📖

AD Neurovascular and Cerebral Vasculature Therapy Companies

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-neurovascular-cerebral

Related Entities

companies-ad-neurovascular-cerebral-vasculature-therapy-companies

Metadata

slug	companies-ad-neurovascular-cerebral-vasculature-therapy-companies
entity_type	company
kg_node_id	None

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (410)

mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

mentions🧪LRP1-Dependent Tau Uptake Disruption70%

mentions🧪Circadian-Synchronized LRP1 Pathway Activation70%

mentions🧪Synthetic Biology BBB Endothelial Cell Reprogramming70%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides70%

mentions🧪Purinergic Signaling Polarization Control70%

mentions🧪Lipid Droplet Dynamics as Phenotype Switches70%

mentions🧪Mechanosensitive Ion Channel Reprogramming70%

see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St70%

see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime70%

see_also📖Extracellular Vesicle and Tunneling Nanotube-Mediated Spread70%

see_also📖Cerebral Amyloid Angiopathy in Neurodegeneration70%

see_also📖Cerebral Amyloid Angiopathy Pathway in Neurodegeneration70%

see_also📖Endosomal-Lysosomal Pathway in Neurodegeneration70%

see_also📖Endosomal Sorting Defects in Neurodegeneration70%

see_also📖Neurovascular Unit Dysfunction in Neurodegeneration70%

see_also📖PPAR Signaling Pathway in Neurodegeneration70%

see_also📖RNA-Targeted Therapies in Neurodegeneration70%

see_also📖Senescent Cell Clearance in Neurodegeneration70%

see_also📖Cell-Free DNA Biomarkers in Neurodegeneration65%

see_also📖Exosomal Biomarkers in Neurodegeneration65%

see_also📖Exosomal miR-155 in Neurodegeneration65%

see_also📖IL-6 (Interleukin-6) in Neurodegeneration65%

see_also📖Liquid Biopsy in Neurodegeneration65%

see_also📖Metabolomic Biomarkers in Neurodegeneration65%

see_also📖Neuroimaging Biomarkers for Neurodegeneration65%

see_also📖Synaptic Biomarkers in Neurodegeneration65%

see_also📖BEACoN Study - Biomarker Exploration in Aging, Cognition and65%

see_also📖Olfactory Mucosa, Blood and Urine for Identification of Earl65%

see_also📖Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration 65%

see_also📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)65%

see_also📖China Neurodegeneration Epidemiology65%

see_also📖DALY Methodology — Neurodegeneration65%

see_also📖Disease Progression & Staging in Neurodegeneration65%

see_also📖Economic Burden — Neurodegeneration65%

see_also📖European Neurodegeneration Epidemiology65%

see_also📖Familial vs Sporadic Neurodegeneration Comparison65%

see_also📖Global Neurodegeneration Epidemiology65%

see_also📖India Neurodegeneration Epidemiology65%

see_also📖Japan Neurodegeneration Epidemiology65%

see_also📖Manganese-Related Neurodegeneration (Manganism)65%

see_also📖mitochondrial-dysfunction-neurodegeneration-comparison65%

see_also📖Mitochondrial Diseases and Neurodegeneration Comparison Matr65%

see_also📖Mitochondrial Membrane Protein-Associated Neurodegeneration 65%

see_also📖Neurodegeneration with Brain Iron Accumulation (NBIA)65%

see_also📖Potential Impact Measures — Neurodegeneration65%

see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)65%

see_also📖PLA2G6-Associated Neurodegeneration (PLAN)65%

see_also📖Sleep Disorders in Neurodegeneration65%

see_also📖US Neurodegeneration Epidemiology65%

see_also📖acetylcholine-signaling-neurodegeneration65%

see_also📖Advanced Glycation End Products in Neurodegeneration65%

see_also📖Advanced In Vitro Models for Neurodegeneration — Organoids, 65%

see_also📖Amylin Signaling in Neurodegeneration65%

see_also📖Antibody Therapy in Neurodegeneration65%

see_also📖Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration65%

see_also📖Autosis Pathway in Neurodegeneration65%

see_also📖Axon Guidance Pathways in Neurodegeneration65%

see_also📖Basal Ganglia Circuit Dysfunction in Neurodegeneration65%

see_also📖becn1-autophagy-initiation-neurodegeneration-causal-chain65%

see_also📖CaMKII Signaling Pathway in Neurodegeneration65%

see_also📖Carbonic Anhydrase Modulator Therapy in Neurodegeneration65%

see_also📖Cholinergic System Dysfunction in Neurodegeneration65%

see_also📖Chrononutrition and Time-Restricted Eating in Neurodegenerat65%

see_also📖Neural Circuits in Neurodegeneration65%

see_also📖Cognitive Reserve and Resilience in Neurodegeneration65%

see_also📖Computational Disease Models for Neurodegeneration65%

see_also📖Convergent Pathways in Neurodegeneration65%

see_also📖Copper Homeostasis in Neurodegeneration65%

see_also📖COVID-19 Neurodegeneration Mechanism65%

see_also📖Diffusion MRI (DTI) in Neurodegeneration65%

see_also📖Digital Phenotyping in Neurodegeneration65%

see_also📖Down Syndrome Neurodegeneration Pathway65%

see_also📖Dystrophic Neurites in Neurodegeneration65%

see_also📖Endocannabinoid System in Neurodegeneration65%

see_also📖Endothelin Signaling Pathway in Neurodegeneration65%

see_also📖epigenetics-neurodegeneration65%

see_also📖ESCRT-III Inhibition by Alpha-Synuclein in Neurodegeneration65%

see_also📖FA2H-Associated Neurodegeneration Pathway65%

see_also📖Farnesoid X Receptor (FXR) Signaling in Neurodegeneration65%

see_also📖Galectin-3 Mechanism in Neurodegeneration65%

see_also📖Gangliosides in Neurodegeneration65%

see_also📖GDF15/GDF11 Signaling in Neurodegeneration65%

see_also📖GDNF Signaling Pathway in Neurodegeneration65%

see_also📖Ghrelin Signaling Pathway in Neurodegeneration65%

see_also📖Glucocorticoid Signaling Pathway in Neurodegeneration65%

see_also📖Glycosylation in Neurodegeneration65%

see_also📖gp130/IL-6 Family Cytokine Signaling in Neurodegeneration65%

see_also📖Hippocampal Neurogenesis in Neurodegeneration65%

see_also📖Histone Modification Pathways in Neurodegeneration65%

see_also📖HMGB1 Signaling in Neurodegeneration65%

see_also📖Homocysteine Neurotoxicity and Neurodegeneration65%

see_also📖IGF-1 Signaling Pathway in Neurodegeneration65%

see_also📖IL-1 Signaling Pathway in Neurodegeneration65%

see_also📖Integrated Stress Response in Neurodegeneration65%

see_also📖interleukin-6-signaling-neurodegeneration65%

see_also📖Intrinsic Apoptosis Pathway in Neurodegeneration65%

see_also📖Ion Channel Dysfunction in Neurodegeneration: Cross-Disease 65%

see_also📖Kidney-Brain Neurodegeneration Axis65%

see_also📖Lipid Dysregulation in Neurodegeneration65%

see_also📖Lipid Metabolism Dysregulation in Neurodegeneration65%

see_also📖Lysosomal Calcium Dysregulation in Neurodegeneration65%

see_also📖Magnetic Resonance Spectroscopy in Neurodegeneration65%

see_also📖Metal Homeostasis Dysregulation in Neurodegeneration65%

see_also📖Metal Homeostasis in Neurodegeneration65%

see_also📖Microglial Priming Pathway in Neurodegeneration65%

see_also📖MicroRNA Dysfunction in Neurodegeneration65%

see_also📖Mineralocorticoid Receptor Signaling in Neurodegeneration65%

see_also📖Mitochondrial Dynamics Pathway in Neurodegeneration65%

see_also📖Mitochondrial Fusion in Neurodegeneration65%

see_also📖Molecular Chaperones in Neurodegeneration65%

see_also📖mTOR Signaling in Neurodegeneration65%

see_also📖mTOR Signaling Pathway in Neurodegeneration65%

see_also📖Neural Circuit Disruption in Neurodegeneration65%

see_also📖Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in N65%

see_also📖Neurofilament Light Chain (NfL) Mechanism in Neurodegenerati65%

see_also📖Neuronal Hyperexcitability in Neurodegeneration65%

see_also📖Neuropil Threads in Neurodegeneration65%

see_also📖Neurotensin Signaling in Neurodegeneration65%

see_also📖NF-kB Signaling Pathway in Neurodegeneration65%

see_also📖Nitric Oxide Signaling in Neurodegeneration65%

see_also📖Noradrenergic Signaling Pathway in Neurodegeneration65%

see_also📖Neuropeptide Y Signaling in Neurodegeneration65%

see_also📖NRF2 Signaling Pathway in Neurodegeneration65%

see_also📖Nuclear Pore Complex Dysfunction in Neurodegeneration65%

see_also📖Orexin Signaling in Neurodegeneration65%

see_also📖OSK Reprogramming and Yamanaka Factors in Neurodegeneration65%

see_also📖P-Body (Processing Body) Pathway in Neurodegeneration65%

see_also📖Paranodal Dysfunction in Neurodegeneration65%

see_also📖Paraptosis in Neurodegeneration65%

see_also📖Parthanatos in Neurodegeneration65%

see_also📖Pericyte Loss in Neurodegeneration65%

see_also📖Peripheral Immune-Brain Crosstalk in Neurodegeneration65%

see_also📖PKR Pathway in Neurodegeneration65%

see_also📖Prion Diseases in Neurodegeneration65%

see_also📖Prion-Like Spread in Neurodegeneration65%

see_also📖Prion Protein Metabolism in Neurodegeneration65%

see_also📖Progesterone Signaling Pathway in Neurodegeneration65%

see_also📖Prognostic Biomarkers in Neurodegeneration65%

see_also📖Protein Aggregation Comparison in Neurodegeneration65%

see_also📖Protein Aggregation Seeds in Neurodegeneration65%

see_also📖Protein O-GlcNAcylation Pathway in Neurodegeneration65%

see_also📖Cortical Involvement and Neurodegeneration in Progressive Su65%

see_also📖Purinergic Signaling in Neurodegeneration65%

see_also📖Quantum Biology and Coherent Energy Transfer in Neurodegener65%

see_also📖R-Loop Stress in Neurodegeneration65%

see_also📖RAN Translation in Neurodegeneration65%

see_also📖Retinal Degeneration Pathway in Neurodegeneration65%

see_also📖Ribosome Dysfunction in Neurodegeneration65%

see_also📖RNA Splicing in Neurodegeneration65%

see_also📖Ribonuclease κ and Circular RNAs: A New Mechanism of Aging a65%

see_also📖S100 Protein Signaling Pathway in Neurodegeneration65%

see_also📖Serotonergic Dysfunction in Neurodegeneration65%

see_also📖Sex Differences in Neurodegeneration65%

see_also📖Short Chain Fatty Acids in Neurodegeneration65%

see_also📖Sigma-1 Receptor Signaling in Neurodegeneration65%

see_also📖Sirtuin-Mitochondrial Biogenesis Axis in Neurodegeneration65%

see_also📖Sleep Dysfunction in Neurodegeneration65%

see_also📖SUMOylation in Neurodegeneration65%

see_also📖synaptic-vesicle-cycling-neurodegeneration65%

see_also📖Synthetic Lethality and PARP Inhibition in Neurodegeneration65%

see_also📖T-Cell Dysfunction in Neurodegeneration65%

see_also📖Tertiary Lymphoid Organs in Neurodegeneration65%

see_also📖Therapeutic Targets in Neurodegeneration65%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration65%

see_also📖ubiquitin-proteasome-dysfunction-neurodegeneration65%

see_also📖Ubiquitin-Proteasome System Dysfunction in Neurodegeneration65%

see_also📖Vagus Nerve Pathway in Neurodegeneration65%

see_also📖VEGF Signaling and Cerebral Angiogenesis in Neurodegeneratio65%

see_also📖vip-vasoactive-intestinal-peptide-signaling-neurodegeneratio65%

see_also📖WNK1-Bilirubin Signaling in Neuroinflammation and Neurodegen65%

see_also📖Wnt/β-Catenin Signaling Pathway in Neurodegeneration65%

see_also📖Cross-National Cancer-Dementia Correlation and Shared Diseas60%

see_also📖Cancer-Dementia Inverse Correlation: Epidemiological Evidenc60%

see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 55%

see_also📖Long-term Effects of Hearing Intervention on Brain Health in55%

see_also📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial55%

see_also📖Blood-Brain Barrier Dysfunction and Therapeutic Delivery for55%

see_also📖Geniposide for Alzheimer's disease - immune biomarker t55%

mentions🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

mentions🧪APOE Isoform Conversion Therapy50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

mentions🧪Glymphatic System-Enhanced Antibody Clearance Reversal50%

mentions🧪SASP-Driven Aquaporin-4 Dysregulation50%

mentions🧪Aquaporin-4 Polarization Rescue50%

mentions🧪Ganglioside Rebalancing Therapy50%

mentions🧪Arginine Methylation Enhancement Therapy50%

mentions🧪Complement C1q Mimetic Decoy Therapy50%

mentions🧪CYP46A1 Overexpression Gene Therapy50%

mentions🧪SIRT6-NAD+ Axis Enhancement Therapy50%

mentions🧪PARP1 Inhibition Therapy50%

mentions🧪Hypocretin-Neurogenesis Coupling Therapy50%

mentions🧪Orexin-Microglia Modulation Therapy50%

mentions🧪Lysosomal Calcium Channel Modulation Therapy50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th50%

mentions🧪Glial Glycocalyx Remodeling Therapy50%

mentions🧪R-Loop Resolution Enhancement Therapy50%

mentions🧪HCN1-Mediated Resonance Frequency Stabilization Therapy50%

mentions🧪TET2-Mediated Demethylation Rejuvenation Therapy50%

mentions🧪Selective Acid Sphingomyelinase Modulation Therapy50%

mentions🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)50%

mentions🧪Purinergic P2Y12 Inverse Agonist Therapy50%

mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%

mentions🧪Near-infrared light therapy stimulates COX4-dependent mitoch50%

see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease50%

see_also📖p-Tau Biomarker in Immunoglobulin Light Chain and Transthyre50%

see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease50%

see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers50%

see_also📖Digital Therapeutic Platform for Swallowing and Drooling Pro50%

see_also📖Utilisation of Health Services and Quality of Life in Atypic50%

see_also📖Phase 3 Study to Compare the Efficacy and Safety of Masitini50%

see_also📖LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE50%

see_also📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M50%

see_also📖A Multicenter, Phase III, Randomized, Double Blind, Placebo-50%

see_also📖A 6-month & 18-month Prospective, Randomized, Placebo-co50%

see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI50%

see_also📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451650%

see_also📖PCDH19-Related Epilepsy (EFMR) — Preclinical Gene Therapy Pr50%

see_also📖Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pi50%

see_also📖CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subc50%

see_also📖Hereditary Sensory and Autonomic Neuropathy (HSAN)50%

see_also📖MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acid50%

see_also📖Mirror Therapy and Sensory Re-education in Corticobasal Synd50%

see_also📖Physical and Occupational Therapy in Corticobasal Syndrome50%

see_also📖Healthcare Economics and Cost of Illness in Progressive Supr50%

see_also📖PSP and Idiopathic Normal Pressure Hydrocephalus: Clinical O50%

see_also📖Speech Therapy and Communication Aids in Corticobasal Syndro50%

see_also📖ABCA7 Lipid Transport and Microglial Phagocytosis AD Causal 50%

see_also📖APOE4 and Alzheimer's Disease Risk50%

see_also📖Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP50%

see_also📖Braak Staging and Tau Propagation Pathway50%

see_also📖Multimodal Diagnostic Algorithm for CBS and PSP50%

see_also📖CBS/PSP Panxoneopathy and Membrane Biology50%

see_also📖Glial Tau Pathology in PSP and CBD50%

see_also📖Glymphatic Clearance Hypothesis — Impaired Aβ and Tau Remova50%

see_also📖Glymphatic and Vascular Clearance Dysfunction in 4R-Tauopath50%

see_also📖Neuroinflammation in Parkinson's Disease Dementia and D50%

see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease50%

see_also📖Systemic Infection and Tau Pathology Acceleration50%

see_also📖Tau Seeding and Propagation Pathway50%

see_also📖ALS Therapeutic Landscape — Programs by Phase and Modality50%

see_also📖AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integration45%

see_also📖Alpha-Synuclein PET Imaging and Biomarker Advances45%

see_also📖Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)45%

see_also📖Imaging Biomarkers for Corticobasal Syndrome and Progressive45%

see_also📖Multi-Analyte Biomarker Panel for Parkinson's Disease D45%

see_also📖Polygenic Risk Score Integration Panel for Alzheimer's 45%

see_also📖CSF and Blood Biomarkers in Progressive Supranuclear Palsy45%

see_also📖Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh45%

see_also📖BLAAC PD - Black and African Americans Connections to PD (NC45%

see_also📖Clostridium Butyricum for Motor and Non-motor Symptoms in Pa45%

see_also📖CNversyt and Megan Rodden ALS Trials45%

see_also📖Cognitive and Speech Rehabilitation in CBS (NCT05823421)45%

see_also📖First-in-Human 4R Tau Ligand Study in PSP (NCT07348276)45%

see_also📖Gait Analysis Parameter and Upper Limb Evaluation in Neurolo45%

see_also📖Gait and Upper Limb Evaluation in PSP (NCT07136844)45%

see_also📖GBA Brain Molecular Imaging and Blood Biomarkers for Precisi45%

see_also📖Safety and Clinical Outcomes Study: Amniotic and Umbilical C45%

see_also📖A Phase III, Randomized, Double-Blind, Placebo-Controlled, M45%

see_also📖A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C45%

see_also📖A Phase 3, Randomized, Double-blind, Placebo-controlled, Par45%

see_also📖Master Screening Study to Determine Individuals With Potenti45%

see_also📖Whole-Body Photobiomodulation for Motor and Cognitive Change45%

see_also📖PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD45%

see_also📖Quality of Life and Caregiver Burden in PSP (NCT03638505)45%

see_also📖Silymarin for Neuroprotection and Symptom Management in Park45%

see_also📖Social Behaviors and Quality of Life in Parkinson's Dis45%

see_also📖Clinical Efficacy and Mechanism of tDCS for Dysphagia in Par45%

see_also📖alexander-disease45%

see_also📖Alexander Disease Genetic Variants45%

see_also📖APOE4 (Apolipoprotein E4)45%

see_also📖ATP13A9 and Parkinson's Disease45%

see_also📖Callosal Disconnection and Interhemispheric Dysfunction in C45%

see_also📖Caregiver Burden and Support in Corticobasal Syndrome45%

see_also📖Caregiver Support and Palliative Care in Atypical [Parkinson45%

see_also📖Clinical Phenotypes and Subtypes of Corticobasal Syndrome45%

see_also📖Natural History and Prognosis of Corticobasal Syndrome45%

see_also📖Dysphagia and Nutritional Management in Corticobasal Syndrom45%

see_also📖Environmental Toxins and Parkinson's Risk45%

see_also📖HIV-Associated Neurocognitive Disorders (HAND)45%

see_also📖Hemiballismus and Hemichorea in Corticobasal Syndrome45%

see_also📖Investment Landscape: ALS45%

see_also📖Investment Landscape: Frontotemporal Dementia45%

see_also📖Investment Landscape: Huntington's Disease45%

see_also📖Investment Landscape: Parkinson's Disease45%

see_also📖Japanese and German Case Series in Corticobasal Degeneration45%

see_also📖Jervell and Lange-Nielsen Syndrome45%

see_also📖LRRK2 Gene Variants and Mutations45%

see_also📖Nutritional Support and Dietary Interventions in Corticobasa45%

see_also📖Postural Dysfunction and Abnormalities in Corticobasal Syndr45%

see_also📖Pseudobulbar Affect and Emotional Lability in Corticobasal S45%

see_also📖Quality of Life and Caregiver Burden in Progressive Supranuc45%

see_also📖Speech and Voice Disorders in PSP45%

see_also📖Sandhoff Disease45%

see_also📖Sialorrhea and Drooling in Corticobasal Syndrome45%

see_also📖Simultanagnosia and Balint's Syndrome in Corticobasal S45%

see_also📖SNCA Gene Variants and Mutations45%

see_also📖Vocational Rehabilitation and Driving in Corticobasal Syndro45%

see_also📖Voice and Speech in Corticobasal Syndrome45%

see_also📖SNCA — Alpha-Synuclein Gene Entity Page45%

see_also📖Alzheimer's Disease Mechanism Index45%

see_also📖Shared Mechanisms Between Alzheimer and Parkinson Disease45%

see_also📖ALS Biomarkers and Disease Monitoring45%

see_also📖C9orf72 Repeat Expansions in CBS and PSP45%

see_also📖Myoclonus and Cortical Hyperexcitability in Corticobasal Syn45%

see_also📖VEGF and Angiogenesis Dysregulation in CBS/PSP45%

see_also📖Pupillometry and Chromatic Pupillometry in Corticobasal Synd45%

see_also📖FTDP-17 Clinical Phenotypes and Disease Progression45%

see_also📖FTLD-TDP Subtypes and Mechanisms45%

see_also📖GBA Glucocerebrosidase Dysfunction and Parkinson's Dise45%

see_also📖Iron and Neuromelanin Accumulation in PSP45%

see_also📖LRRK2 Kinase Activation and Endolysosomal Dysfunction in Par45%

see_also📖MSA Clinical Features and Diagnosis45%

see_also📖mTOR Signaling in Autophagy and Lysosomal Function45%

see_also📖Neuroresilience Mechanisms and Evidence45%

see_also📖NLRP3 Inflammasome Inhibitors for Parkinson's Disease45%

see_also📖NLRP3 Inhibitors in Parkinson's Disease: Research and C45%

see_also📖Pesticides and Parkinson Disease (Pest-PD) — NCT0642031045%

see_also📖Advanced Proteolysis and Ubiquitin System Targeting in CBS/P45%

see_also📖Gait and Balance Disorders in Progressive Supranuclear Palsy45%

see_also📖HLA Haplotypes and Neuroinflammatory Profiles in PSP45%

see_also📖PSP Liquid-Liquid Phase Separation and Biomolecular Condensa45%

see_also📖PSP Lysosomal Dysfunction and Autophagy Impairment45%

see_also📖Metabolic Dysfunction and Insulin Resistance in Progressive 45%

see_also📖Pupillary and Visual Dysfunction in Progressive Supranuclear45%

see_also📖PSP Tau Propagation and Spreading Mechanisms45%

see_also📖PSP Weight Loss and Cachexia45%

see_also📖Sleep Architecture Changes in CBS and PSP45%

see_also📖Somatic Mutations and Brain Mosaicism45%

see_also📖Speech and Language Deficits in Corticobasal Syndrome45%

see_also📖Synaptic Loss and Dysfunction Pathway45%

see_also📖Tau Kinase Signaling Cascade in Alzheimer's Disease45%

see_also📖TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain45%

mentions🔬Senescent cell clearance as neurodegeneration therapy40%

mentions🧪Retinal Vascular Microcirculation Rescue40%

mentions🧪Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat40%

mentions🔬What are the mechanisms underlying senolytic therapy for age40%

mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%

related🧪Ganglioside Rebalancing Therapy40%

related🧪PARP1 Inhibition Therapy40%